Published in Hepatitis Weekly, April 15th, 2002
Due to various reasons, patients with hepatocellular carcinoma (HCC), a primary form of liver cancer, are not always good candidates for tumor resection. Doctors in Hong Kong are now recommending that in those instances, systemic therapy consisting of a combination of cisplatin, interferon (IFN)-(alpha), doxorubicin, and 5-fluorouracil, also known as PIAF, may be sufficient for extending patient survival, particularly in those whose bilirubin levels remain low and who do not have...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.